Christopher Maisel

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

Paul G. Richardson, Albert Oriol, Alessandra Larocca et al. · Journal of Clinical Oncology · 2020 · 155 citations · Full text

Medicine, Oncology, Pharmacology +14

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

Nizar J. Bahlis, Michael H. Tomasson, Mohamad Mohty et al. · Blood · 2022 · 52 citations

Medicine, Oncology, Pharmacology +14

Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.

Ajay K. Nooka, Alexander M. Lesokhin, Mohamad Mohty et al. · Journal of Clinical Oncology · 2023 · 42 citations

Medicine, Oncology, Pharmacotherapy +14

Report of a Phase II Study of Clofarabine and Cytarabine in De Novo and Relapsed and Refractory AML Patients and in Selected Elderly Patients at High Risk for Anthracycline Toxicity

Edward Agura, Barry Cooper, Houston Holmes et al. · The Oncologist · 2011 · 30 citations · Full text

Medicine, Oncology, Pharmacology +17

O6-benzylguanine and BCNU in multiple myeloma: a phase II trial

Eric D. Batts, Christopher Maisel, Donna Kane et al. · Cancer Chemotherapy and Pharmacology · 2007 · 28 citations

Medicine, Hematology, Oncology +13